In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Low-carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling prospective studies

Session Poster Session 6

Speaker Maciej Banach

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Nutrition, Malnutrition and Heart Disease
  • Session type : Poster Session
  • FP Number : P5409

Authors : M Mazidi (Gothenburg,SE), N Katsiki (Thessaloniki,GR), DP Mikhailidis (London,GB), M Banach (Lodz,PL)

Authors:
M. Mazidi1 , N. Katsiki2 , D.P. Mikhailidis3 , M. Banach4 , 1Chalmers University of Technology, Department of Biology and Biological Engineering, Food and Nutrition Science - Gothenburg - Sweden , 2Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine - Thessaloniki - Greece , 3University College London, Department of Clinical Biochemistry - London - United Kingdom , 4Medical University of Lodz, Department of Hypertension - Lodz - Poland ,

On behalf: International Lipid Expert Panel (ILEP)

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1112-1113

Background: Little is known on the long-term association between low-carbohydrate diets (LCD) and mortality.

Purpose: We aimed to evaluate the link between LCD with total and cause-specific mortality by applying on both individual data and pooling prospective studies.

Methods: Data from National Health and Nutrition Examination Survey (NHANES) (1999–2010) were collected. We used adjusted Cox regression to determine the risk ratio (RR) and 95% confidence interval (95% CI), as well as random effects models and generic inverse variance methods to synthesize quantitative and pooling data, followed by a leave-one-out method for sensitivity analysis.

Results: Based on the data from NHANES with 24825 participants (mean age of 47.6 years, comprising 48.6% men and 51.4% women), after adjustment, participants in the top quartile (Q4) of LCD had the highest risk of total (32%; hazard ratio [HR] 1.32 [1.14–2.01], p<0.001), cardiovascular (CVD) (50%; 1.50 [1.12–2.31], p<0.001), cerebrovascular (51%; 1.51 [1.19–1.91], p<0.001) and cancer (36%; 1.36 [1.09–1.83], p<0.001) mortality. In the same model, the association between LCD and total mortality was stronger in the non-obese (0.48%) than in the obese (19%) participants. Findings based on the meta-analysis of 7 prospective cohorts with 447,506 participants and 39,326 mortality cases indicted a positive association between LCD and total (RR: 1.15, 95% CI: 1.07–1.22, p<0.001, I2=8.6) (figure 1A), CVD (RR: 1.13, 95% CI: 1.02–1.24, p<0.001, I2=11.2) (figure 1B) and cancer mortality (RR: 1.07, 95% CI: 1.01–1.14, p=0.02, I2=10.3). These findings were robust in sensitivity analyses.

Conclusions: Our study highlighted the unfavorable effect of LCD on total and cause-specific mortality, based on both individual data and by pooling previous cohort studies. Given the fact that LCDs may be unsafe, it would be preferable not to currently recommend these diets. Further studies to clarify the mechanisms involved in these associations and to support our findings are eagerly awaited.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are